Lazard Asset Management LLC Buys 2,644 Shares of Charles River Laboratories International, Inc. $CRL

Lazard Asset Management LLC grew its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 13.2% in the first quarter, according to its most recent disclosure with the SEC. The fund owned 22,637 shares of the medical research company’s stock after buying an additional 2,644 shares during the period. Lazard Asset Management LLC’s holdings in Charles River Laboratories International were worth $3,905,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Cardinal Capital Management grew its position in Charles River Laboratories International by 0.6% during the fourth quarter. Cardinal Capital Management now owns 10,928 shares of the medical research company’s stock worth $2,180,000 after buying an additional 62 shares in the last quarter. Asset Management One Co. Ltd. raised its holdings in Charles River Laboratories International by 4.0% in the 4th quarter. Asset Management One Co. Ltd. now owns 1,847 shares of the medical research company’s stock valued at $375,000 after acquiring an additional 71 shares in the last quarter. Mercer Global Advisors Inc. ADV raised its holdings in Charles River Laboratories International by 1.3% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 6,316 shares of the medical research company’s stock valued at $1,260,000 after acquiring an additional 80 shares in the last quarter. Advisory Services Network LLC lifted its position in shares of Charles River Laboratories International by 2.6% in the 3rd quarter. Advisory Services Network LLC now owns 3,226 shares of the medical research company’s stock worth $505,000 after acquiring an additional 83 shares during the period. Finally, Brown Miller Wealth Management LLC lifted its position in shares of Charles River Laboratories International by 7.0% in the 1st quarter. Brown Miller Wealth Management LLC now owns 1,278 shares of the medical research company’s stock worth $220,000 after acquiring an additional 84 shares during the period. Institutional investors own 98.91% of the company’s stock.

Analysts Set New Price Targets

CRL has been the topic of a number of research reports. Weiss Ratings upgraded Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 1st. Royal Bank Of Canada initiated coverage on Charles River Laboratories International in a research report on Tuesday, April 14th. They issued an “outperform” rating and a $215.00 target price for the company. BNP Paribas Exane set a $250.00 price target on shares of Charles River Laboratories International in a research note on Wednesday, July 1st. Barclays boosted their price target on shares of Charles River Laboratories International from $210.00 to $220.00 and gave the company an “overweight” rating in a report on Friday, May 8th. Finally, Mizuho increased their price objective on shares of Charles River Laboratories International from $192.00 to $230.00 and gave the company a “neutral” rating in a research note on Monday, July 13th. Eleven analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Charles River Laboratories International currently has an average rating of “Moderate Buy” and an average price target of $220.75.

Charles River Laboratories International Stock Performance

Charles River Laboratories International stock opened at $232.49 on Friday. The firm has a market capitalization of $11.20 billion, a P/E ratio of -61.83, a P/E/G ratio of 2.61 and a beta of 1.40. The stock has a fifty day moving average price of $206.60 and a two-hundred day moving average price of $188.14. Charles River Laboratories International, Inc. has a 52-week low of $144.26 and a 52-week high of $242.73. The company has a debt-to-equity ratio of 0.90, a current ratio of 1.36 and a quick ratio of 1.03.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Thursday, May 7th. The medical research company reported $2.06 EPS for the quarter, beating the consensus estimate of $1.96 by $0.10. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The company had revenue of $995.83 million for the quarter, compared to the consensus estimate of $977.46 million. During the same quarter in the previous year, the company earned $2.34 EPS. The firm’s revenue for the quarter was up 1.2% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. As a group, analysts anticipate that Charles River Laboratories International, Inc. will post 11.05 EPS for the current fiscal year.

Insider Transactions at Charles River Laboratories International

In related news, Director James C. Foster sold 75,000 shares of Charles River Laboratories International stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $225.00, for a total transaction of $16,875,000.00. Following the completion of the transaction, the director directly owned 31,596 shares of the company’s stock, valued at $7,109,100. This trade represents a 70.36% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.30% of the stock is owned by corporate insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.